The Pharma Data

JANUARY 6, 2021

He continues: “With the green light granted by the FDA to continue our clinical research, we are one step closer to offering psoriasis patients a novel, improved oral treatment option and thereby enhancing their quality of life. The following files are available for download: View original content: [link]. Source link.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

AUGUST 7, 2020

Results included global public and private financing from regenerative medicine and advanced therapy developers, and highlighted a 120 per cent increase over the first half of 2019. The ARM report also showcased robust pipelines of therapies targeting indications in cancers, infectious diseases and inherited disorders.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

NOVEMBER 25, 2020

CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique properties for treatment of inflammatory diseases. The majority of the work will be completed in 2021 to start clinical trials as early as possible during 2022. The Company’s validated, proprietary F.I.R.S.T

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. View original content to download multimedia: [link]. For more information, please visit: www.innoventbio.com. SOURCE Innovent Biologics, Inc. Source link.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

The Pharma Data

DECEMBER 14, 2020

a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announced today that the company has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) pertaining to its drug candidate Rabeximod. STOCKHOLM , Dec. About Cyxone. SOURCE Cyxone.

FDA 40

FDA Clinical Trials Clinical Development Treatment 40

The Pharma Data

JANUARY 27, 2021

Batoclimab (HBM9161) , a fully human anti-FcRn mAb, blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases. “In China, large numbers of patients suffer IgG-mediated autoimmune diseases including MG, ITP, NMOSD, among others.

Therapies 40

Therapies Treatment International Licensing 40

The Pharma Data

DECEMBER 29, 2020

HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company was officially included into the Shenzhen-Hong Kong Stock Connect program (the “Hong Kong Stock Connect”).

Clinical Development 52

Clinical Development FDA Regulations Clinical Trials 52

The Pharma Data

NOVEMBER 23, 2020

NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. View original content to download multimedia: [link]. . ROCKVILLE, Md. , .

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

21, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. View original content to download multimedia: [link].

Treatment 40

Treatment Pharmaceuticals Drug Development Science 40

The Pharma Data

OCTOBER 18, 2020

Oncopeptides plans to initiate clinical development of OPD5 with an open-label phase 1, dose escalation study on safety and tolerability of OPD5 as a myeloablative regimen followed by Autologous Stem Cell Transplantation in patients with relapsed refractory multiple myeloma. About Oncopeptides. SOURCE Oncopeptides AB.

FDA 40

FDA Drugs Pharmaceutical Companies Treatment 40

The Pharma Data

JANUARY 31, 2021

These findings give confidence that Clover’s COVID-19 vaccine candidates are suitable for further clinical development.” Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins. View original content to download multimedia: [link].

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

DECEMBER 16, 2020

“Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. ” As previously announced, the planned trial will evaluate the efficacy of Berubicin in patients with GBM who have failed primary treatment for their disease.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. View original content to download multimedia: [link]. .

Clinical Trials 52

Clinical Trials FDA Trials Production 52

PPD

NOVEMBER 30, 2023

Researchers can leverage big data analytic approaches to help predict how a compound will interact with the population, which can then be followed by less invasive clinical trials to validate clinical benefits. Together, we will leverage these trends to accelerate your drug development initiatives into the new year and beyond.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

The Pharma Data

JANUARY 13, 2021

Fast Track designation facilitates the development and expedites the review of drugs that are intended to treat serious and life-threatening conditions and show the potential to fill an unmet medical need. A preprint supporting Brilacidin’s COVID-19 treatment potential can be downloaded at the link below.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

The Pharma Data

NOVEMBER 4, 2020

A partial response was observed in one patient with renal cell cancer and 10 patients with different advanced cancers showed stable disease lasting ? In addition, clinical biomarker data confirm proof of mechanism in patients. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc.

Packaging 40

Packaging Clinical Development Disease Drugs 40

The Pharma Data

JANUARY 14, 2021

Clinical Development – Pipeline Review. His research interests span a range of areas across renal medicine and include glomerular disease, multi-system renal disease and complications of chronic kidney disease, in particular renal associated anemia. End.

Clinical Trials 40

Clinical Trials Disease Hospitals International 40

The Pharma Data

JANUARY 17, 2021

a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2a clinical study of the company’s lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma.

Treatment 52

Treatment Trials FDA Approval RNA 52

The Pharma Data

JANUARY 17, 2021

. “This result provides a foundation for a clinical development program using higher doses of setanaxib across a variety of orphan indications. The following files are available for download: View original content: [link]. ”, said CEO Renée Aguiar-Lucander. Forward-Looking Statements.

Trials 40

Trials Clinical Trials Pharmacokinetics Small Molecule 40

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

SEPTEMBER 16, 2020

Amgen’s clinical development team and clinical investigators, will discuss Phase 1 data being presented on the Company’s investigational KRAS G12C ?inhibitor Eligible patients were heavily pretreated with at least two or more prior lines of treatment, consistent with their tumor type and stage of disease.

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

JANUARY 4, 2021

The most recent data from the Surveillance, Epidemiology, and End Results Program (SEER) of the US National Cancer Institute (NCI) estimated 19,940 new cases of AML and 11,180 deaths from this disease in the United States in 2020. Any of these intentions may alter in light of future development. ” Reference.

FDA 40

FDA Therapies Drugs Treatment 40

The Pharma Data

JUNE 26, 2021

. “Even with the availability of vaccines and declines in deaths from COVID-19 in various parts of the world, we continue to see new hospitalisations from severe forms of the disease,” said Levi Garraway, M.D., Roche’s Chief Medical Officer and Head of Global Product Development.

FDA 40

FDA Treatment Clinical Trials Virus 40

The Pharma Data

SEPTEMBER 20, 2020

” Sotorasib demonstrated confirmed objective response rate (ORR) and disease control rates (DCR) of 35.3% Amgen’s clinical development team and clinical investigators, will discuss Phase 1 data being presented on the Company’s investigational KRAS G12C ?inhibitor Amgen, along with members of?Amgen’s

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

DECEMBER 15, 2020

The Diamyd Medical data includes relevant information about disease progression, drug effects and clinical trial design. For more information on reporting on diabetes, download our journalists’ guide: Diabetes in the News: A Guide for Journalists on Reporting on Diabetes (PDF, 3MB). About Diamyd Medical. Source link.

Drug Development 40

Drug Development Clinical Trials Trials Vaccine 40

Codon

MARCH 24, 2024

The real cost is clinical development. In 2012, an Israeli company called Protalix gained approval for their plant-based enzyme product for Gaucher’s disease. Kanuma, their FDA-approved protein product for rare lysosomal diseases, is “purified from the egg white of transgenic hens.” Why rock the boat?

Engineering 84

Engineering Vaccine Production RNA 84

The Pharma Data

OCTOBER 14, 2020

FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on the results from two randomized, controlled trials (HARMONY CTP and HARMONY 1) from the clinical development program for WAKIX. WAKIX is not recommended in patients with end-stage renal disease (ESRD). Adverse Reactions.

FDA Approval 40

FDA Approval FDA Treatment Clinical Trials 40

Agency IQ

APRIL 8, 2024

Since these issues could occur during the investigational phase of clinical development as well as in the post-marketing setting—and product status could very well differ by country/region—ICH members determined that these guidelines should be developed to facilitate the exchange of information in both settings.

FDA 40

FDA Production Regulations Vaccine 40

The Pharma Data

OCTOBER 25, 2020

SQI is accelerating the clinical development of its direct-to-consumer COVID-19 HOME Antibody Test, its COVID-19 RALI-dx Severity Triage Test and its COVID-19 RALI- fast Severity Triage Point-of-Care (POC) Test. View original content to download multimedia: [link]. SQI Diagnostics, Inc.

FDA 52

FDA Hospitals Clinical Development FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. Body of the abstract: Background.

Vaccine 40

Vaccine Trials Treatment Virus 40

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has cleared Armata’s IND to initiate a clinical trial of its lead therapeutic candidate, AP-PA02, in Pseudomonas aeruginosa infections. . Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. .

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Drugs 52

The Pharma Data

JANUARY 26, 2021

. “Multi-drug resistant bacterial infections are a serious and growing public health threat, and with two strong therapeutic candidates and a robust team to drive clinical development, we believe we are well positioned to be a leader in the innovative field of phage therapy,” said Todd R. .

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Production 52

The Pharma Data

JANUARY 25, 2021

. “ This marks our second strategic agreement with Asieris, a well-run and well-capitalized company that is executing ahead of plan on the clinical development of Cevira ®, which we licensed to them in July 2019. but with a healthcare system that is still developing. ” said Kevin Pan Ph.D., SOURCE Photocure.

Clinical Development 40

Clinical Development Licensing Licensing Production 40

The Pharma Data

NOVEMBER 4, 2020

Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. Research and development.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52